Researchers to develop bioinks using unique hydrogel
(LOS ANGELES)– The Terasaki Institute for Biomedical Innovation (TIBI) has formally signed a collaborative agreement with Tetratherix™, a company which produces Tetramatrix, a synthetic injectable hydrogel currently being clinically tested in a variety of biomedical applications.
Tetramatrix exhibits superior injectability, responsiveness to body temperature and tunable properties. It is also highly biocompatible and biodegradable and because it is purely synthetic, it is not subject to the regulatory and manufacturing restrictions of animal or human-derived products. The unique and advantageous features of Tetramatrix offers the potential for further development into biocompatible, adhesive bioinks for deep tissue applications.
“This venture leverages TIBI’s multi-year expertise in bio-ink materials development and optimization, as well as its long history of achievement in 3D bioprinting,” said TIBI’s Chief Innovation Officer, Maurizio Vecchione.
The TIBI researchers aim to use Tetramatrix to produce an optimized bioink for multiple applications.
“This project will allow us to conduct world-class research in collaboration with TIBI to further expand our product pipeline in key therapeutic areas,” said Ali Fathi, Tetratherix™ Founder and Director.
It is the hope that by optimizing the Tetramatrix bioinks, the TIBI researchers can help to translate them into viable biomedical applications. Tetratherix™ is particularly interested in creating an injectable cardiac patch for cardiovascular conditions and to use the bioinks for additional applications such as bone graft substitutes and skin grafts.